Abstract
Sickle Cell Disease (SCD) is a hereditary red blood cell disorder characterized by hemolytic anemia, periodic painful ischemic vascular occlusion and long-term multiorgan failure. Pathophysiology of SCD is not completely understood and disease phenotypes vary
largely. The only curative treatment is hematopoietic stem cell transplantation. This is however limited in its availability and not without risks. ERN-EuroBloodNet now leads a SCD use case within the GenoMed4All initiative.